Medpace Holdings, Inc. (NASDAQ:MEDP) Given Average Recommendation of “Moderate Buy” by Brokerages

Medpace Holdings, Inc. (NASDAQ:MEDP) has received an average rating of “Moderate Buy” from the eight brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $424.14.

Several equities research analysts have recently weighed in on the company. Mizuho started coverage on Medpace in a report on Tuesday, May 28th. They issued a “buy” rating and a $435.00 price target on the stock. Robert W. Baird decreased their target price on Medpace from $469.00 to $430.00 and set an “outperform” rating for the company in a research report on Wednesday. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and boosted their target price for the company from $340.00 to $450.00 in a research note on Tuesday, April 23rd. William Blair reaffirmed an “outperform” rating on shares of Medpace in a research note on Tuesday. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a research report on Wednesday.

Insider Transactions at Medpace

In other Medpace news, CEO August J. Troendle sold 4,782 shares of the firm’s stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $400.58, for a total value of $1,915,573.56. Following the completion of the sale, the chief executive officer now directly owns 716,197 shares in the company, valued at $286,894,194.26. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Medpace news, CEO August J. Troendle sold 4,782 shares of the firm’s stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $400.58, for a total value of $1,915,573.56. Following the completion of the sale, the chief executive officer now owns 716,197 shares of the company’s stock, valued at $286,894,194.26. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO August J. Troendle sold 3,987 shares of the business’s stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $395.22, for a total value of $1,575,742.14. Following the sale, the chief executive officer now owns 660,351 shares in the company, valued at approximately $260,983,922.22. The disclosure for this sale can be found here. Insiders have sold a total of 29,621 shares of company stock valued at $11,816,852 in the last 90 days. Insiders own 20.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in MEDP. Rise Advisors LLC acquired a new position in shares of Medpace in the 1st quarter valued at $27,000. Mather Group LLC. purchased a new stake in Medpace during the 1st quarter valued at about $28,000. GAMMA Investing LLC acquired a new position in shares of Medpace in the fourth quarter valued at about $30,000. Fidelis Capital Partners LLC purchased a new position in shares of Medpace in the first quarter worth about $31,000. Finally, McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Medpace during the fourth quarter worth about $33,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Down 0.4 %

NASDAQ MEDP opened at $380.50 on Friday. Medpace has a 52 week low of $227.21 and a 52 week high of $459.77. The firm has a market capitalization of $11.79 billion, a price-to-earnings ratio of 38.79, a PEG ratio of 1.76 and a beta of 1.36. The company has a fifty day moving average of $404.55 and a two-hundred day moving average of $381.65.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, July 22nd. The company reported $2.75 EPS for the quarter, topping analysts’ consensus estimates of $2.54 by $0.21. Medpace had a net margin of 16.74% and a return on equity of 59.91%. The firm had revenue of $528.10 million during the quarter, compared to analysts’ expectations of $528.41 million. During the same period in the previous year, the company earned $1.93 EPS. The firm’s revenue for the quarter was up 14.6% compared to the same quarter last year. Equities research analysts anticipate that Medpace will post 11.33 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.